PSMA2 | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
natural killer cell	25 studies	32% ± 11%	Explore
B cell	21 studies	32% ± 13%	Explore
fibroblast	21 studies	35% ± 15%	Explore
endothelial cell	20 studies	37% ± 15%	Explore
CD4-positive, alpha-beta T cell	19 studies	25% ± 7%	Explore
smooth muscle cell	17 studies	35% ± 11%	Explore
pericyte	17 studies	35% ± 12%	Explore
T cell	16 studies	29% ± 15%	Explore
conventional dendritic cell	16 studies	35% ± 15%	Explore
CD8-positive, alpha-beta T cell	15 studies	27% ± 10%	Explore
mast cell	13 studies	30% ± 8%	Explore
epithelial cell	13 studies	38% ± 20%	Explore
macrophage	13 studies	36% ± 16%	Explore
classical monocyte	12 studies	33% ± 9%	Explore
dendritic cell	11 studies	41% ± 20%	Explore
monocyte	11 studies	34% ± 12%	Explore
endothelial cell of lymphatic vessel	11 studies	40% ± 12%	Explore
non-classical monocyte	11 studies	37% ± 13%	Explore
regulatory T cell	11 studies	26% ± 8%	Explore
basal cell	11 studies	35% ± 16%	Explore
plasma cell	10 studies	32% ± 14%	Explore
plasmacytoid dendritic cell	9 studies	45% ± 11%	Explore
connective tissue cell	9 studies	40% ± 14%	Explore
endothelial cell of vascular tree	9 studies	33% ± 9%	Explore
mature NK T cell	8 studies	26% ± 6%	Explore
gamma-delta T cell	8 studies	32% ± 13%	Explore
plasmablast	7 studies	54% ± 18%	Explore
naive B cell	7 studies	25% ± 8%	Explore
capillary endothelial cell	7 studies	25% ± 8%	Explore
myofibroblast cell	7 studies	42% ± 13%	Explore
vein endothelial cell	7 studies	29% ± 12%	Explore
memory B cell	7 studies	23% ± 3%	Explore
ciliated cell	7 studies	40% ± 7%	Explore
leukocyte	6 studies	31% ± 7%	Explore
CD16-negative, CD56-bright natural killer cell, human	6 studies	27% ± 8%	Explore
CD16-positive, CD56-dim natural killer cell, human	6 studies	28% ± 9%	Explore
epithelial cell of proximal tubule	6 studies	41% ± 19%	Explore
progenitor cell	6 studies	39% ± 16%	Explore
myeloid cell	6 studies	28% ± 10%	Explore
secretory cell	6 studies	29% ± 9%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	5 studies	26% ± 9%	Explore
naive thymus-derived CD8-positive, alpha-beta T cell	5 studies	28% ± 10%	Explore
endothelial cell of artery	5 studies	36% ± 10%	Explore
enterocyte	5 studies	24% ± 5%	Explore
goblet cell	5 studies	31% ± 16%	Explore
alveolar macrophage	4 studies	19% ± 4%	Explore
effector CD8-positive, alpha-beta T cell	4 studies	26% ± 6%	Explore
renal alpha-intercalated cell	4 studies	49% ± 10%	Explore
abnormal cell	4 studies	31% ± 18%	Explore
enteroendocrine cell	4 studies	36% ± 17%	Explore
intestinal crypt stem cell	4 studies	31% ± 10%	Explore
mesothelial cell	4 studies	47% ± 18%	Explore
transit amplifying cell	4 studies	31% ± 17%	Explore
mucosal invariant T cell	4 studies	26% ± 3%	Explore
innate lymphoid cell	4 studies	26% ± 9%	Explore
T-helper 17 cell	4 studies	33% ± 9%	Explore
type I pneumocyte	3 studies	33% ± 15%	Explore
pancreatic A cell	3 studies	41% ± 20%	Explore
mononuclear phagocyte	3 studies	45% ± 15%	Explore
effector memory CD8-positive, alpha-beta T cell	3 studies	25% ± 6%	Explore
hematopoietic precursor cell	3 studies	47% ± 24%	Explore
glomerular endothelial cell	3 studies	27% ± 6%	Explore
kidney loop of Henle epithelial cell	3 studies	36% ± 3%	Explore
kidney distal convoluted tubule epithelial cell	3 studies	66% ± 22%	Explore
neural crest cell	3 studies	48% ± 3%	Explore
retinal ganglion cell	3 studies	55% ± 20%	Explore
extravillous trophoblast	3 studies	51% ± 3%	Explore
placental villous trophoblast	3 studies	67% ± 4%	Explore
erythroblast	3 studies	55% ± 21%	Explore
precursor B cell	3 studies	35% ± 9%	Explore
pro-B cell	3 studies	33% ± 11%	Explore
microglial cell	3 studies	25% ± 7%	Explore
intraepithelial lymphocyte	3 studies	25% ± 5%	Explore
erythrocyte	3 studies	46% ± 21%	Explore
neuron	3 studies	52% ± 17%	Explore
granulocyte	3 studies	45% ± 11%	Explore
oligodendrocyte precursor cell	3 studies	32% ± 11%	Explore
hepatocyte	3 studies	39% ± 26%	Explore
CD8-positive, alpha-beta memory T cell	3 studies	33% ± 13%	Explore
T follicular helper cell	3 studies	21% ± 3%	Explore
immature B cell	3 studies	36% ± 22%	Explore
CD4-positive, alpha-beta memory T cell	3 studies	20% ± 1%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
lung	11 studies	32% ± 14%	Explore
peripheral blood	9 studies	32% ± 7%	Explore
intestine	9 studies	30% ± 14%	Explore
brain	6 studies	24% ± 7%	Explore
kidney	5 studies	36% ± 10%	Explore
liver	5 studies	33% ± 25%	Explore
uterus	4 studies	34% ± 5%	Explore
prostate	4 studies	23% ± 5%	Explore
pancreas	3 studies	41% ± 18%	Explore
placenta	3 studies	52% ± 8%	Explore
eye	3 studies	28% ± 13%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
esophagus	100%	4076.21	1445 / 1445	26%	0.36	47 / 183
lung	100%	4143.41	577 / 578	8%	0.17	94 / 1155
kidney	100%	3948.11	89 / 89	4%	0.07	39 / 901
brain	100%	2517.38	2632 / 2642	4%	0.06	31 / 705
bladder	100%	3643.10	21 / 21	4%	0.12	20 / 504
stomach	100%	3805.39	359 / 359	4%	0.13	11 / 286
intestine	100%	4029.16	966 / 966	3%	0.06	18 / 527
skin	100%	4506.41	1809 / 1809	2%	0.02	8 / 472
ovary	100%	3190.64	180 / 180	2%	0.02	7 / 430
uterus	100%	3473.84	170 / 170	2%	0.04	7 / 459
breast	100%	4413.59	459 / 459	1%	0.04	16 / 1118
prostate	100%	4153.11	245 / 245	1%	0.02	7 / 502
pancreas	100%	2461.91	328 / 328	1%	0.05	2 / 178
thymus	100%	3476.70	653 / 653	1%	0.01	4 / 605
adrenal gland	100%	5095.01	258 / 258	0%	0.00	1 / 230
adipose	100%	4588.50	1204 / 1204	0%	0	0 / 0
liver	100%	4081.77	226 / 226	0%	0	0 / 406
muscle	100%	6302.01	803 / 803	0%	0	0 / 0
spleen	100%	4097.96	241 / 241	0%	0	0 / 0
blood vessel	100%	4304.46	1334 / 1335	0%	0	0 / 0
heart	97%	3213.31	839 / 861	0%	0	0 / 0
peripheral blood	85%	4080.74	786 / 929	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
eye	0%	0	0 / 0	0%	0	0 / 80
gingiva	0%	0	0 / 0	0%	0	0 / 0
lymph node	0%	0	0 / 0	0%	0	0 / 29
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
tonsil	0%	0	0 / 0	0%	0	0 / 45
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0009615	Biological process	response to virus
GO_0043161	Biological process	proteasome-mediated ubiquitin-dependent protein catabolic process
GO_0000932	Cellular component	P-body
GO_0000502	Cellular component	proteasome complex
GO_0034774	Cellular component	secretory granule lumen
GO_1904813	Cellular component	ficolin-1-rich granule lumen
GO_0070062	Cellular component	extracellular exosome
GO_0005839	Cellular component	proteasome core complex
GO_0005654	Cellular component	nucleoplasm
GO_0005829	Cellular component	cytosol
GO_0005576	Cellular component	extracellular region
GO_0019773	Cellular component	proteasome core complex, alpha-subunit complex
GO_0005737	Cellular component	cytoplasm
GO_0005634	Cellular component	nucleus
GO_0005515	Molecular function	protein binding

IV. Literature review

[source]

Gene name	PSMA2
Protein name	Proteasome subunit alpha type-2 (Macropain subunit C3) (Multicatalytic endopeptidase complex subunit C3) (Proteasome component C3) Proteasome subunit alpha type Proteasome (Prosome, macropain) subunit, alpha type, 2, isoform CRA_a Proteasome 20S subunit alpha 2
Synonyms	HC3 DKFZp686D09174 PSC3 hCG_19883
Description	FUNCTION: Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). .
Accessions	ENST00000223321.9 P25787 H3BT36 H7C3A7 Q6MZI6 ENST00000457444.6 C9JCK5 ENST00000433579.1 ENST00000436986.5 ENST00000442788 A0A024RA52 ENST00000445517.1

PSMA2 report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review